A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1. 1. This was a randomized, double-blind comparison of the efficacy and safety of venlafaxine and fluoxetine in outpatients with major depression. 2. 2. Three hundred fourteen patients were randomly assigned to either venlafaxine 37.5 mg twice daily or fluoxetine 20 mg once daily for a maximum of 8...

Full description

Saved in:
Bibliographic Details
Published in:Progress in neuro-psychopharmacology & biological psychiatry 1996, Vol.20 (1), p.57-71
Main Authors: Dieric, Michel, Ravizza, Ujigi, Realini, Renzo, Martin, Alain
Format: Article
Language:English
Subjects:
Adult
Aged
Antidepressive Agents, Second-Generation - therapeutic use
Biological and medical sciences
Cyclohexanols - therapeutic use
Depressive Disorder - drug therapy
Double-Blind Method
Female
fluoxetine
Fluoxetine - therapeutic use
Humans
major depression
Male
Medical sciences
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
venlafaxine
Venlafaxine Hydrochloride
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:1. 1. This was a randomized, double-blind comparison of the efficacy and safety of venlafaxine and fluoxetine in outpatients with major depression. 2. 2. Three hundred fourteen patients were randomly assigned to either venlafaxine 37.5 mg twice daily or fluoxetine 20 mg once daily for a maximum of 8 weeks. 3. 3. If the response was inadequate after two weeks of treatment, the dosage of venlafaxine could be increased to 75 mg twice daily. 4. 4. A clinical response, defined as at least a 50% decrease from baseline in the total HAM-D score, was attained at week 6 in 72% of patients on venlafaxine and 60% of patients on fluoxetine (p = 0.023). 5. 5. Among patients who increased their dose at 2 weeks, venlafaxine was significantly (p < 0.05) superior from week 3 onward on the HAM-D. 6. 6. Venlafaxine 75 mg daily is comparable to fluoxetine, but at 150 mg daily, it may be superior to fluoxetine in outpatients with major depression who do not respond early to treatment.
ISSN:0278-5846
1878-4216
DOI:10.1016/0278-5846(95)00292-8